Effectiveness and duration of additional immune defense provided by SARS-CoV-2 infection before and after receiving the mRNA COVID-19 vaccine BNT162b2

• Published in: Vaccine: X Vol. 19; p. 100518
• Main Authors: Shimada, Nagashige, Sugawa, Satoshi, Murakami, Satoshi, Shinoda, Masahiro, Ota, Shinichiro, Morikawa, Miwa, Takei, Hiroaki, Serizawa, Yusuke, Takahashi, Hidenori, Toyama-Kousaka, Mio, Matsuse, Hiroto, Shinkai, Masaharu
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.08.2024; Elsevier
• Subjects: BNT162b2; COVID-19; Hybrid immunity; IgG; Regular paper; SARS-CoV-2 nucleocapsid protein; SARS-CoV-2 spike protein receptor-binding domain; P1; P2; BNT162b2; P3; BI; IgG; SARS-CoV-2 spike protein receptor-binding domain; N; and P4; COVID-19; Hybrid immunity; SARS-CoV-2 nucleocapsid protein; RBD; NI

Our investigation focused whether infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) before or after receiving the mRNA COVID-19 vaccine can increase immune protection. And we also investigated relationship of infection acquired. Three shots of the mRNA coronavirus disease 2...